Achieve Life Sciences reports Q4/FY 2022 net loss $42.4M; cash $24.8M; phase 3/2 trial data due Q2 2023

ACHIEVE LIFE SCIENCES, INC.

Cash, cash equivalents, and restricted cash totaled $24.8M as of Dec 31, 2022.
Net loss for FY 2022 was $42.4M; Q4 2022 net loss $11.2M.
Phase 3 ORCA-3 and Phase 2 ORCA-V1 top-line results expected in Q2 2023.
Closed $18.9M private placement in Nov 2022 to fund trials and working capital.
USPTO granted patent for cytisinicline mesylate salt formulation, expiring 2042.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.